Clinical Trial Update: A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy [Phase 3]

View source ↗

Summary

Phase 3 study of droxidopa in symptomatic neurogenic orthostatic hypotension, including participants with Parkinson's disease, multiple system atrophy, pure aut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dopamine Beta-hydroxylase Deficiency
• Multiple System Atrophy
• Neurogenic Orthostatic Hypotension
• Parkinson Disease
• Pure Autonomic Failure

Drugs mentioned

• Northera (droxidopa)

Snippet

Sponsor: Chelsea Therapeutics | Conditions: Symptomatic Neurogenic Orthostatic Hypotension, Parkinson's Disease | Phase 3 | Status: TERMINATED | Results posted: 2016-01-08